Based on the results, it can be tentatively concluded that the factors influencing the effectiveness of omalizumab in the treatment of allergic asthma are total serum IgE and the presence of comorbidity (p-values of 0.039 and 0.046, respectively), with patients with a high total serum IgE and comorbidity being less likely to respond and potentially showing a lower effectiveness in treatment. The gene discussed is IGHE; the disease is allergic asthma.